Deadline for applications extended to Sept 14, 2009 – Ontario challenges other provinces to compete
In an effort to expand the reach of the competition and to ensure that all provinces are represented, Ontario has put forth a challenge to all other provinces to encourage companies to submit. Ontario always has strong representation, which is great, but we have not seen the interest this year from other provinces. While the economic downturn has affected areas across the country and investment levels are low everywhere, the Canada’s Top 10™ Competition is an ideal way for innovative companies to get in front of active investors or potential partners—both essential to growing companies.
To find out more about the competition visit http://www.topcanadiancompanies.ca
To find out how to become a Promotional Partner contact Janna Glenn (613) 828-6274 x301 or jglenn@ocri.ca.
RESOLUTE Partners Selects BelAir Networks for U.S. Military Wi-Fi Network Deployments
Southington, CT – RESOLUTE Partners, the leading provider of personal public internet access in the U.S. Military market, has selected BelAir Networks market-leading Wi-Fi solutions for RESOLUTE customers around the world. BelAir Networks comprehensive Wi-Fi product line and RESOLUTE’s powerful network OSS, installation, service and support operations deliver a carrier class communications experience to both end-users and network customers.
For more information, go to http://www.belairnetworks.com/news/press_releases/view.cfm?p_id=194
ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
August 5, 2009 – Halifax, Nova Scotia – ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with UK-based Scancell Ltd., the operating company of Scancell Holdings Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT’s DepoVax™ delivery system for Scancell’s novel ImmunoBody® DNA vaccines.
“Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration,” remarked Dr. Marc Mansour, vice president of R&D at IVT. “Our DepoVax™ technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques.”
http://www.immunovaccine.com/press-releases.php#182
Canada’s Top 10™ Competition Application Deadline Extended to August 21, 2009
WHAT:
Canada’s Top 10™ Competition promotes the 10 most promising life science, cleantech and information communications technology companies from across Canada to Canadian and international investors and potential strategic partners.
WHY:
Become one of Canada’s Top 10 TM companies this year and gain access to financing opportunities, new markets and strategic partners through:
- greater exposure to international investors and industry insiders that are important to your continued growth and success;
- access to industry experts at an annual coaching session; and
- access to active investors through a series of investment forums in Boston, New York, San Francisco and Washington D.C.
WHO:
Start-up, early stage and emerging companies who are actively seeking financing in the areas of life science, cleantech and ICT are eligible for the competition.
WHEN:
Deadline for applications is: Friday, August 21, 2009.
WHERE:
Apply online at www.topcanadiancompanies.ca
About OCRI:
Leading the way for Ottawa, OCRI is the city’s economic development agency. OCRI is the rallying point to bring business, education, research and talent together to create the winning economic conditions that allow Ottawa’s knowledge-based companies to thrive locally and compete globally. At OCRI we promote sustainable economic development to maintain our high quality of life. For more information on OCRI visit our website at www.ocri.ca and for more information on the Ottawa Region please visit www.ottawaregion.com.
For more information, please contact
OCRI
Kim Cunningham
Manager, External Communications
Office: 613-828-6274 ext. 256
Cell: 613-851-0768
kcunningham@ocri.ca
ImmunoVaccine Technologies Secures National Research Council of Canada Industrial Research Assistance Program Funding
July 23, 2009 – Halifax, Nova Scotia – ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has received a non-repayable contribution of up to $260,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). The funding, in addition to both technical and business-oriented advisory services, will support IVT’s development of a pipeline of proprietary therapeutic cancer and infections disease vaccines.
“Using our proprietary DepoVax™ technology, we are developing vaccines that have the potential to stimulate a long-lasting immune response in a single dose,” said Dr. Randal Chase, president and CEO of IVT. “NRC-IRAP has been instrumental in supporting our efforts to leverage the potential of our technology, including strengthening our patent protection along the way.”
http://www.immunovaccine.com/press-releases.php#181
ImmunoVaccine Technologies Secures National Research Council of Canada Industrial Research Assistance Program Funding
HALIFAX, NS, July 23 /CNW/ – ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has received a non-repayable contribution of up to $260,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). The funding, in addition to both technical and business-oriented advisory services, will support IVT’s development of a pipeline of proprietary therapeutic cancer and infections disease vaccines.
“Using our proprietary DepoVax(TM) technology, we are developing vaccines that have the potential to stimulate a long-lasting immune response in a single dose,” said Dr. Randal Chase, president and CEO of IVT. “NRC-IRAP has been instrumental in supporting our efforts to leverage the potential of our technology, including strengthening our patent protection along the way.”
http://www.newswire.ca/en/releases/archive/July2009/23/c8051.html
iCo Therapeutics Closes Non-Brokered Private Placement
July 16, 2009 VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) (“iCo” or the “Company”) is pleased to announce that it has completed a non-brokered private placement in the amount of $475,000 through the issuance of 1,187,500 common shares in the capital of the Company at a subscription price of $0.40 per share. The Company intends to use the net proceeds for working capital and general corporate purposes.
A finder’s fee of 7% will be payable to certain arm’s length third parties with respect to a portion of the private placement. All securities issued in the private placement are subject to a four month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.
Kane Biotech Granted United States Patent for Oral Care Technology
WINNIPEG, Manitoba (July 15, 2009) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce the issuance of Patent No. 7,556,807 entitled “Signal peptides, nucleic acid molecules and methods for treatment of caries” by the U.S. Patent and Trademark Office. This is the second patent to issue protecting Kane Biotech’s CSP (Competence Stimulating Peptide) technology.
The ‘807 patent discloses and claims a method of inhibiting dental plaque and treating plaque- associated conditions such as dental caries and periodontal disease using analogues of CSP peptide in oral care formulations. Dr. Dennis Cvitkovitch (Dental Research Institute, University of Toronto), discoverer of CSP in Streptococcus mutans demonstrated the ability of CSP analogue peptides to inhibit streptococcal biofilm (dental plaque) formation.
http://www.kanebiotech.com/press_releases/press_release071509.htm
ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens
July 14, 2009 – Halifax, Nova Scotia – ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax™ delivery platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company will fast-track DPX-0907 into Phase 1 clinical trials.
“Advanced-stage breast, ovarian and prostate cancers remain devastating and challenging diseases that urgently need treatment options, and we are excited to use Immunotope’s antigens in our platform” said Dr. Randal Chase, president & CEO of IVT. “This licensing agreement significantly advances our cancer immunotherapy capabilities and represents our continued commitment to developing our DepoVax™ technology within a robust clinical trial program.”
http://www.immunovaccine.com/press-releases.php#177
Redknee Secures Contract with Leading Asia Pacific Operator
Redknee’s Service Bureau to Provide Wholesale Billing and Content Settlement for Tier-1 Wireless Operator
TORONTO– July 7, 2009 – Redknee (TSX: RKN), a leading provider of business-critical billing and charging software and solutions for communications service providers, announced that a leading Tier-1 operator from the Asia Pacific (APAC) region has selected Redknee’s InBill solution to manage its wholesale billing with its Mobile Virtual Network Operator (MVNO) partners through Redknee’s service bureau operations. The operator joins an extensive line-up of service providers who leverage Redknee’s wholesale billing expertise to maximize the value of their networks by effectively and efficiently managing multi-party settlements.
http://www.redknee.com/news_events/news_releases/298